Efficacy and Safety Study of PEX168 in Monotherapy Diabetes Mellitus Type 2 Patients

Type 2 Diabetes Mellitus Clinical Trial

Official title:

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase IIIa Clinical Study Evaluating PEGylated Loxenatide Injection（PEX168）in Monotherapy of Type 2 Diabetes Mellitus

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02477865
• Other study ID #: PEX168-301
• Status: Active, not recruiting
• Phase: Phase 3
• First received: May 28, 2015
• Last updated: January 21, 2017
• Start date: March 23, 2014
• Est. completion date: February 2017

Study information

• Verified date: January 2016
• Source: Jiangsu Hansoh Pharmaceutical Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase III, multicenter, randomized, double-blind, placebo-controlled study planning to include approximately 387 T2DM patients who have received at least 8 weeks of treatment with diet control and exercise； have not received any glucose-lowering agents within the 8 weeks prior to screening; and have inadequately controlled blood glucose.The subjects would receive PEX168 or placebo monotherapy for 52weeks in total.

Description:

This study consists of 4 periods： Period 1：Up to 3 weeks of screening period. Period 2：A 4-week PEX168 dummy run-in period. Period 3：A 52-week treatment period (including a 24-week core treatment period and a 28-week extended treatment period).

Period 4: A 4-week safety follow-up period. This study will last for approximately 63 weeks, including up to approximately 60 clinic visits.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 406
• Est. completion date: February 2017
• Est. primary completion date: May 15, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 78 Years

Eligibility

Inclusion Criteria (all of the 8 must be met):

1. Type 2 diabetes mellitus confirmed by the 1999 WHO criteria;

2. Men or women;

3. Age at signing the ICF=18 years and =78 years;

4. Body mass index (BMI) 20-40 Kg/m2;

5. At least 8 weeks of treatment with diet control and exercise received prior to screening;

6. No glucose-lowering agents received within the 8 weeks prior to screening;

7. 7.5%=HbA1c=11.0% at screening(local or centralized test); 7.0%=HbA1c=10.5% at randomization(centralized test),and FBG< 13.9 mmol/L(local test);

8. Ability to understand the procedures and approach of this study, willingness to complete the study in strict compliance with the protocol and to voluntarily sign the ICF.

Exclusion criteria:

1. Investigator suspecting the subject of allergy to the study drug;

2. Use of any of the following medications or therapies prior to screening:

1. GLP-1 receptor agonists, GLP-1 analogues, DPP-4 inhibitors or any other incretin analogues.

2. Growth hormone therapy within the 6 months prior to screening;

3. History of drug abuse or alcohol abuse;

4. Participation in any clinical trial within the 3 months prior to screening;

5. Prolonged intravenous, oral or intraarticular treatment with corticosteroids within the 2 months prior to screening;

6. Use of any weight control agents or surgeries within the 2 months prior to screening;

7. Any medications used prior to screening that at the investigator's discretion may confound the interpretation of the efficacy or safety data;

3. History or evidence of any of the following conditions prior to screening:

1. Type 1 diabetes mellitus, single gene mutation DM, DM associated with pancreatic injury,or secondary DM;

2. History of hypertension with SBP>160 mmHg and/or DBP>100 mmHg;

3. History of acute/chronic pancreatitis, history of symptomatic cholecystopathy;

4. History of myeloid C-cell carcinoma, history of multiple endocrine neoplasm (MEN) 2A or 2B syndrome, or related familiar history;

5. Gastric emptying disorders, severe chronic gastrointestinal disorders;

6. History of severe hypoglycemia, unconsciousness or severe hypoglycemia history;

7. Significant hematological disorders, or any diseases;

8. Severe diabetic complications that in the opinion of the investigator make the subject not suitable to participate in this study;

9. Tumors of any organ or system that not been treated within the 5 years prior to screening;

10. Coronary angioplasty, coronary stenting, coronary artery bypass, uncompensated heart failure (NYHA Class III or IV), within the 6 months prior to screening;

11. Acute metabolic complications within the 6 months prior to screening;

12. Thyroid dysfunction within the 6 months prior to screening;

13. Blood lipid disorders within the 6 months prior to screening;

14. Any severe trauma or severe infection within the 1 month prior to screening;

4. Laboratory indicators meeting any of the following criteria prior to screening:

1. ALT>2.5×ULN and/or AST>2.5×ULN and/or total bilirubin>2.5×ULN;

2. Hemoglobin=100 g/L;

3. Serum creatinine>1.5×UNL and eGFR < 45 ml/min/1.73 m2; eGFR is calculated as:186.3 ×[(Serum Creatinine(mmol/L)/88.4)]-1.154 × [Age (years)]- 0.203 × 1.223 × 0.742 (Females) or ×1(Males)

4. Serum thyroid-stimulating hormone(TSH) out of the reference range that is assessed as clinically significant by the investigator;

5. Fasting TGL>5.64 mmol/L(500 mg/dl);

6. Blood amylase and urine amylase>ULN that is assessed as clinically significant by the investigator;

7. Any clinically significant laboratory abnormalities;

5. Clinically significant 12-lead ECG abnormalities;

6. Blood donation or loss=400 mL,or receipt of blood donation within the 4 weeks prior to screening;

7. Pregnant or lactating women, or men or women of child-bearing potential not willing to take contraceptive measures during the study;

8. Any other conditions of the subject that at the investigator's discretion may compound the interpretation of the efficacy or safety data.

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Type 2 Diabetes Mellitus

Intervention

Drug:
• PEX168(100µg)
100µg,Subcutaneous injection,once a week. continued for 52 weeks
• PEX168(200µg)
200µg,Subcutaneous injection,once a week. continued for 52 weeks
• Placebo
0.5ml,Subcutaneous injection,once a week.continued for 24 weeks,then use PEX168 100µg or 200µg qw sc.for 28 weeks.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	HbA1c	To evaluate the HbA1c change from baseline to treatment Week 24 when receiving PEX 168 as compared to the placebo, given on the basis of diet control and exercise.	Baseling to 24 weeks
Secondary	The proportion of HbA1c <6.5% and <7% at the end of the analysis.	The proportion of HbA1c <6.5% and <7% at the end of the analysis, and the proportion receiving salvage therapy.	Baseling to 24 weeks
Secondary	Fasting plasma glucose		Baseling to 52 weeks
Secondary	6 points glucose of fingertip	Each test point of time was before breakfast, 2 hours after breakfast, before lunch,2 hours after lunch , dinner, 2 hours after dinner.This test was performed four times including baseline,V19,V31 and V59.	Baseling to 24 and 52 weeks
Secondary	Postprandial blood glucose two hours		Baseling to 24 weeks
Secondary	Postprandial blood glucose two hours AUC		Baseling to 24 weeks
Secondary	Lipid		Baseling to 52 weeks
Secondary	Weight measured by standardized procedure.	Collect weight data in the morning of screening period, baseline,4,8,12,18,24,38,52 weeks by standardized procedure.	Baseling to 52 weeks
Secondary	Blood pressure	Collect blood pressure data in the morning of screening period, baseline,4,8,12,18,24,38,52 weeks by standardized procedure.	Baseling to 52 weeks
Secondary	Number of Participants with Adverse Events as a Measure of Safety and Tolerability		Baseling to 56 weeks